| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Anemia, Hemolytic, Autoimmune; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Multiple Sclerosis | Details |
| BI-1206 | 6G-11; BI-1206 | Phase 2 Clinical | Bioinvent International Ab | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours; Waldenstrom Macroglobulinemia | Details |
| BI-1607 | BI-1607 | Phase 2 Clinical | Bioinvent International Ab | Adenocarcinoma; Breast Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Skin Melanoma; Solid tumours; Stomach Neoplasms; Uveal melanoma | Details |
| NVG-2089 | NVG-2089 | Phase 2 Clinical | Nuvig Therapeutics Inc | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic | Details |
| S-4321 | S-4321 | Phase 1 Clinical | Seismic Therapeutics Inc | Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Dermatitis, Atopic; Immune System Diseases; Lupus Erythematosus, Cutaneous; Psoriasis | Details |